Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 139

1.

Accuracy of a Rapid Diagnostic Test for the Presence of Direct Oral Factor Xa or Thrombin Inhibitors in Urine-A Multicenter Trial.

Harenberg J, Beyer-Westendorf J, Crowther M, Douxfils J, Elalamy I, Verhamme P, Bauersachs R, Hetjens S, Weiss C.

Thromb Haemost. 2019 Nov 8. doi: 10.1055/s-0039-1700545. [Epub ahead of print]

2.

Rivaroxaban compared with standard anticoagulants for the treatment of acute venous thromboembolism in children: a randomised, controlled, phase 3 trial.

Male C, Lensing AWA, Palumbo JS, Kumar R, Nurmeev I, Hege K, Bonnet D, Connor P, Hooimeijer HL, Torres M, Chan AKC, Kenet G, Holzhauer S, Santamaría A, Amedro P, Chalmers E, Simioni P, Bhat RV, Yee DL, Lvova O, Beyer-Westendorf J, Biss TT, Martinelli I, Saracco P, Peters M, Kállay K, Gauger CA, Massicotte MP, Young G, Pap AF, Majumder M, Smith WT, Heubach JF, Berkowitz SD, Thelen K, Kubitza D, Crowther M, Prins MH, Monagle P; EINSTEIN-Jr Phase 3 Investigators.

Lancet Haematol. 2019 Nov 4. pii: S2352-3026(19)30219-4. doi: 10.1016/S2352-3026(19)30219-4. [Epub ahead of print]

PMID:
31699660
3.

DOACS in women: pros and cons.

Beyer-Westendorf J.

Thromb Res. 2019 Sep;181 Suppl 1:S19-S22. doi: 10.1016/S0049-3848(19)30361-5.

PMID:
31477222
4.

DTI/DXI interferences with global coagulation tests in emergency hospital admissions - Results of the prospective Dresden NOAC Registry (NCT01588119).

Wunder L, Tittl L, Marten S, Beyer-Westendorf J.

Thromb Res. 2019 Oct;182:101-109. doi: 10.1016/j.thromres.2019.08.020. Epub 2019 Aug 22.

PMID:
31476483
5.

Bodyweight-adjusted rivaroxaban for children with venous thromboembolism (EINSTEIN-Jr): results from three multicentre, single-arm, phase 2 studies.

Monagle P, Lensing AWA, Thelen K, Martinelli I, Male C, Santamaría A, Samochatova E, Kumar R, Holzhauer S, Saracco P, Simioni P, Robertson J, Grangl G, Halton J, Connor P, Young G, Molinari AC, Nowak-Göttl U, Kenet G, Kapsa S, Willmann S, Pap AF, Becka M, Twomey T, Beyer-Westendorf J, Prins MH, Kubitza D; EINSTEIN-Jr Phase 2 Investigators.

Lancet Haematol. 2019 Oct;6(10):e500-e509. doi: 10.1016/S2352-3026(19)30161-9. Epub 2019 Aug 13.

PMID:
31420317
6.

Reply: Method agreement analysis and interobserver reliability of the ISTH proposed definitions for effective hemostasis in the management of major bleeding: Methodological issues.

Abdoellakhan RA, Beyer-Westendorf J, Schulman S, Sarode R, Meijer K, Khorsand N.

J Thromb Haemost. 2019 Aug;17(8):1398-1399. doi: 10.1111/jth.14540. No abstract available.

PMID:
31368222
7.

In Reply.

Beyer-Westendorf J.

Dtsch Arztebl Int. 2019 Jun 10;116(23-24):420-421. doi: 10.3238/arztebl.2019.0420b. No abstract available.

8.

International longitudinal registry of patients with atrial fibrillation and treated with rivaroxaban: RIVaroxaban Evaluation in Real life setting (RIVER).

Beyer-Westendorf J, Camm AJ, Fox KAA, Le Heuzey JY, Haas S, Turpie AGG, Virdone S, Kakkar AK; RIVER Registry Investigators.

Thromb J. 2019 Apr 25;17:7. doi: 10.1186/s12959-019-0195-7. eCollection 2019.

9.

Early discharge and home treatment of patients with low-risk pulmonary embolism with the oral factor Xa inhibitor rivaroxaban: an international multicentre single-arm clinical trial.

Barco S, Schmidtmann I, Ageno W, Bauersachs RM, Becattini C, Bernardi E, Beyer-Westendorf J, Bonacchini L, Brachmann J, Christ M, Czihal M, Duerschmied D, Empen K, Espinola-Klein C, Ficker JH, Fonseca C, Genth-Zotz S, Jiménez D, Harjola VP, Held M, Iogna Prat L, Lange TJ, Manolis A, Meyer A, Mustonen P, Rauch-Kroehnert U, Ruiz-Artacho P, Schellong S, Schwaiblmair M, Stahrenberg R, Westerweel PE, Wild PS, Konstantinides SV, Lankeit M; HoT-PE Investigators .

Eur Heart J. 2019 May 23. pii: ehz367. doi: 10.1093/eurheartj/ehz367. [Epub ahead of print]

PMID:
31120118
10.

Treatment and Long-Term Clinical Outcomes of Incidental Pulmonary Embolism in Patients With Cancer: An International Prospective Cohort Study.

Kraaijpoel N, Bleker SM, Meyer G, Mahé I, Muñoz A, Bertoletti L, Bartels-Rutten A, Beyer-Westendorf J, Porreca E, Boulon C, van Es N, Iosub DI, Couturaud F, Biosca M, Lerede T, Lacroix P, Maraveyas A, Aggarwal A, Girard P, Büller HR, Di Nisio M; UPE investigators.

J Clin Oncol. 2019 Jul 10;37(20):1713-1720. doi: 10.1200/JCO.18.01977. Epub 2019 May 22.

PMID:
31116676
11.

Effectiveness and safety of rivaroxaban and warfarin for prevention of major adverse cardiovascular or limb events in patients with non-valvular atrial fibrillation and type 2 diabetes.

Baker WL, Beyer-Westendorf J, Bunz TJ, Eriksson D, Meinecke AK, Sood NA, Coleman CI.

Diabetes Obes Metab. 2019 Sep;21(9):2107-2114. doi: 10.1111/dom.13787. Epub 2019 Jun 11.

PMID:
31099460
12.

Exposure to vitamin k antagonists and kidney function decline in patients with atrial fibrillation and chronic kidney disease.

Posch F, Ay C, Stöger H, Kreutz R, Beyer-Westendorf J.

Res Pract Thromb Haemost. 2019 Mar 5;3(2):207-216. doi: 10.1002/rth2.12189. eCollection 2019 Apr.

13.

Evaluation of unmet clinical needs in prophylaxis and treatment of venous thromboembolism in high-risk patient groups: cancer and critically ill.

Brenner B, Hull R, Arya R, Beyer-Westendorf J, Douketis J, Elalamy I, Imberti D, Zhai Z.

Thromb J. 2019 Apr 15;17:6. doi: 10.1186/s12959-019-0196-6. eCollection 2019. Review.

14.

Treatment of cancer-associated venous thromboembolism in the age of direct oral anticoagulants.

Ay C, Beyer-Westendorf J, Pabinger I.

Ann Oncol. 2019 Mar 27. pii: mdz111. doi: 10.1093/annonc/mdz111. [Epub ahead of print]

15.

Extended anticoagulant therapy in venous thromboembolism: a balanced, fractional factorial, clinical vignette-based study.

Cate VT, Lensing AWA, Weitz JI, Beyer-Westendorf J, Wells PS, Mismetti P, Prandoni P, Cohen AT, Davidson BL, Prins MH.

Haematologica. 2019 Oct;104(10):e474-e477. doi: 10.3324/haematol.2018.209924. Epub 2019 Mar 7. No abstract available.

16.

Non-vitamin K Antagonist Oral Anticoagulants (NOAC) as an Alternative Treatment Option in Tumor-Related Venous Thromboembolism.

Beyer-Westendorf J, Klamroth R, Kreher S, Langer F, Matzdorff A, Riess H.

Dtsch Arztebl Int. 2019 Jan 18;116(3):31-38. doi: 10.3238/arztebl.2019.0031.

17.

Longitudinal kidney function trajectories predict major bleeding, hospitalization and death in patients with atrial fibrillation and chronic kidney disease.

Posch F, Ay C, Stöger H, Kreutz R, Beyer-Westendorf J.

Int J Cardiol. 2019 May 1;282:47-52. doi: 10.1016/j.ijcard.2019.01.089. Epub 2019 Jan 27.

PMID:
30777405
18.

Determinants of the Quality of Warfarin Control after Venous Thromboembolism and Validation of the SAMe-TT2-R2 Score: An Analysis of Hokusai-VTE.

Barco S, Granziera S, Coppens M, Douxfils J, Nijkeuter M, Riva N, Vanassche T, Zhang G, Lin M, Kamphuisen PW, Cohen AT, Beyer-Westendorf J.

Thromb Haemost. 2019 Apr;119(4):675-684. doi: 10.1055/s-0039-1678546. Epub 2019 Feb 7.

PMID:
30731492
19.

Full Study Report of Andexanet Alfa for Bleeding Associated with Factor Xa Inhibitors.

Connolly SJ, Crowther M, Eikelboom JW, Gibson CM, Curnutte JT, Lawrence JH, Yue P, Bronson MD, Lu G, Conley PB, Verhamme P, Schmidt J, Middeldorp S, Cohen AT, Beyer-Westendorf J, Albaladejo P, Lopez-Sendon J, Demchuk AM, Pallin DJ, Concha M, Goodman S, Leeds J, Souza S, Siegal DM, Zotova E, Meeks B, Ahmad S, Nakamya J, Milling TJ Jr; ANNEXA-4 Investigators.

N Engl J Med. 2019 Apr 4;380(14):1326-1335. doi: 10.1056/NEJMoa1814051. Epub 2019 Feb 7.

20.

Method agreement analysis and interobserver reliability of the ISTH proposed definitions for effective hemostasis in management of major bleeding.

Abdoellakhan RA, Beyer-Westendorf J, Schulman S, Sarode R, Meijer K, Khorsand N.

J Thromb Haemost. 2019 Mar;17(3):499-506. doi: 10.1111/jth.14388. Epub 2019 Feb 13.

PMID:
30657628
21.

Impact of Prolonged Anticoagulation with Rivaroxaban on Provoked Venous Thromboembolism Recurrence: IMPROVE-VTE.

Coleman CI, Turpie AGG, Bunz TJ, Beyer-Westendorf J, Baker WL.

Am J Med. 2019 Apr;132(4):498-504. doi: 10.1016/j.amjmed.2018.11.040. Epub 2018 Dec 21.

PMID:
30582894
22.

Incomplete echocardiographic recovery at 6 months predicts long-term sequelae after intermediate-risk pulmonary embolism. A post-hoc analysis of the Pulmonary Embolism Thrombolysis (PEITHO) trial.

Barco S, Russo M, Vicaut E, Becattini C, Bertoletti L, Beyer-Westendorf J, Bouvaist H, Couturaud F, Danays T, Dellas C, Duerschmied D, Empen K, Ferrari E, Galiè N, Jiménez D, Klok FA, Kostrubiec M, Kozak M, Kupatt C, Lang IM, Lankeit M, Meneveau N, Palazzini M, Pruszczyk P, Rugolotto M, Salvi A, Sanchez O, Schellong S, Sobkowicz B, Meyer G, Konstantinides SV.

Clin Res Cardiol. 2019 Jul;108(7):772-778. doi: 10.1007/s00392-018-1405-1. Epub 2018 Dec 18.

23.

American Society of Hematology 2018 guidelines for management of venous thromboembolism: prophylaxis for hospitalized and nonhospitalized medical patients.

Schünemann HJ, Cushman M, Burnett AE, Kahn SR, Beyer-Westendorf J, Spencer FA, Rezende SM, Zakai NA, Bauer KA, Dentali F, Lansing J, Balduzzi S, Darzi A, Morgano GP, Neumann I, Nieuwlaat R, Yepes-Nuñez JJ, Zhang Y, Wiercioch W.

Blood Adv. 2018 Nov 27;2(22):3198-3225. doi: 10.1182/bloodadvances.2018022954.

24.

Comparative risk of major bleeding with rivaroxaban and warfarin: Population-based cohort study of unprovoked venous thromboembolism.

Kohn CG, Bunz TJ, Beyer-Westendorf J, Coleman CI.

Eur J Haematol. 2019 Feb;102(2):143-149. doi: 10.1111/ejh.13185. Epub 2018 Nov 20.

PMID:
30328143
25.

Risk of bleeding and arterial cardiovascular events in patients with splanchnic vein thrombosis in Denmark: a population-based cohort study.

Søgaard KK, Adelborg K, Darvalics B, Horváth-Puhó E, Beyer-Westendorf J, Ageno W, Sørensen HT.

Lancet Haematol. 2018 Oct;5(10):e441-e449. doi: 10.1016/S2352-3026(18)30133-9. Epub 2018 Sep 7.

PMID:
30201587
26.

Health-care Cost Impact of Continued Anticoagulation With Rivaroxaban vs Aspirin for Prevention of Recurrent Symptomatic VTE in the EINSTEIN-CHOICE Trial Population.

Wells PS, Prins MH, Beyer-Westendorf J, Lensing AWA, Haskell L, Levitan B, Laliberté F, Ashton V, Xiao Y, Lejeune D, Crivera C, Lefebvre P, Zhao Q, Yuan Z, Schein J, Prandoni P.

Chest. 2018 Dec;154(6):1371-1378. doi: 10.1016/j.chest.2018.08.1059. Epub 2018 Sep 7.

27.

COSIMO - patients with active cancer changing to rivaroxaban for the treatment and prevention of recurrent venous thromboembolism: a non-interventional study.

Cohen AT, Maraveyas A, Beyer-Westendorf J, Lee AYY, Mantovani LG, Bach M; COSIMO Investigators.

Thromb J. 2018 Sep 4;16:21. doi: 10.1186/s12959-018-0176-2. eCollection 2018.

28.

The prothrombin time does not predict the risk of recurrent venous thromboembolism or major bleeding in rivaroxaban-treated patients.

Ten Cate H, Lensing AWA, Weitz JI, Middeldorp S, Beyer-Westendorf J, Kubitza D, Brighton T, Raskob GE, Mismetti P, Prandoni P, Gebel M, Prins MH.

Thromb Res. 2018 Oct;170:75-83. doi: 10.1016/j.thromres.2018.08.008. Epub 2018 Aug 15.

PMID:
30121419
29.

Long-Term Outcome of Splanchnic Vein Thrombosis in Cirrhosis.

Senzolo M, Riva N, Dentali F, Rodriguez-Castro K, Sartori MT, Bang SM, Martinelli I, Schulman S, Alatri A, Beyer-Westendorf J, Di Minno MND, Ageno W; IRSVT study investigators.

Clin Transl Gastroenterol. 2018 Aug 15;9(8):176. doi: 10.1038/s41424-018-0043-2.

30.

Benefits and risks of extended treatment of venous thromboembolism with rivaroxaban or with aspirin.

Prandoni P, Lensing AWA, Prins MH, Gebel M, Pap AF, Homering M, Bauersachs R, Beyer-Westendorf J, Bounameaux H, Cohen AT, Davidson BL, van Bellen B, Verhamme P, Wells PS, Yuan Z, Levitan B, Weitz JI.

Thromb Res. 2018 Aug;168:121-129. doi: 10.1016/j.thromres.2018.06.009. Epub 2018 Jul 10.

PMID:
30064683
31.

Clinical Impact of Bleeding in Cancer-Associated Venous Thromboembolism: Results from the Hokusai VTE Cancer Study.

Kraaijpoel N, Di Nisio M, Mulder FI, van Es N, Beyer-Westendorf J, Carrier M, Garcia D, Grosso M, Kakkar AK, Mercuri MF, Middeldorp S, Hernandez CR, Santamaria A, Schwocho L, Segers A, Verhamme P, Wang TF, Weitz JI, Zhang G, Zwicker JI, Büller HR, Raskob GE.

Thromb Haemost. 2018 Aug;118(8):1439-1449. doi: 10.1055/s-0038-1667001. Epub 2018 Jul 30.

PMID:
30060256
32.

Sex hormones and venous thromboembolism - from contraception to hormone replacement therapy.

Beyer-Westendorf J, Bauersachs R, Hach-Wunderle V, Zotz RB, Rott H.

Vasa. 2018 Oct;47(6):441-450. doi: 10.1024/0301-1526/a000726. Epub 2018 Jul 16. Review.

33.

Betrixaban for prevention of venous thromboembolism in acute medically ill patients.

Beyer-Westendorf J, Verhamme P, Bauersachs R.

Eur Heart J Suppl. 2018 May;20(Suppl E):E16-E22. doi: 10.1093/eurheartj/suy017. Epub 2018 May 9.

34.

Effectiveness and safety of rivaroxaban versus warfarin in patients with unprovoked venous thromboembolism: A propensity-score weighted administrative claims cohort study.

Coleman CI, Peacock WF, Bunz TJ, Beyer-Westendorf J.

Thromb Res. 2018 Aug;168:31-36. doi: 10.1016/j.thromres.2018.05.031. Epub 2018 May 30.

PMID:
29883907
35.

Effectiveness and safety of rivaroxaban versus warfarin in patients with provoked venous thromboembolism.

Coleman CI, Turpie AGG, Bunz TJ, Beyer-Westendorf J.

J Thromb Thrombolysis. 2018 Oct;46(3):339-345. doi: 10.1007/s11239-018-1695-1.

PMID:
29881958
36.

Diagnosis and Treatment of Pulmonary Embolism in Challenging Populations.

Werth S, Beyer-Westendorf J.

Hamostaseologie. 2018 May;38(2):87-97. doi: 10.1055/s-0038-1641586. Epub 2018 May 29. Review.

PMID:
29843173
37.

Management of major bleeding and outcomes in patients treated with direct oral anticoagulants: results from the START-Event registry.

Testa S, Ageno W, Antonucci E, Morandini R, Beyer-Westendorf J, Paciaroni M, Righini M, Sivera P, Verhamme P, Pengo V, Poli D, Palareti G.

Intern Emerg Med. 2018 Oct;13(7):1051-1058. doi: 10.1007/s11739-018-1877-z. Epub 2018 May 22.

PMID:
29790125
38.

Effectiveness and Safety of Rivaroxaban in Patients With Cancer-Associated Venous Thrombosis.

Kohn CG, Lyman GH, Beyer-Westendorf J, Spyropoulos AC, Bunz TJ, Baker WL, Eriksson D, Meinecke AK, Coleman CI.

J Natl Compr Canc Netw. 2018 May;16(5):491-497. doi: 10.6004/jnccn.2018.7008.

PMID:
29752323
39.

Use of Direct Oral Anticoagulants in Patients with Cancer: Practical Considerations for the Management of Patients with Nausea or Vomiting.

Riess H, Ay C, Bauersachs R, Becattini C, Beyer-Westendorf J, Cajfinger F, Chau I, Cohen AT, Khorana AA, Maraveyas A, Renni M, Young AM.

Oncologist. 2018 Jul;23(7):822-839. doi: 10.1634/theoncologist.2017-0473. Epub 2018 Apr 12. Review.

40.

Risk of recurrent venous thromboembolism according to baseline risk factor profiles.

Prins MH, Lensing AWA, Prandoni P, Wells PS, Verhamme P, Beyer-Westendorf J, Bauersachs R, Bounameaux H, Brighton TA, Cohen AT, Davidson BL, Decousus H, Kakkar AK, van Bellen B, Pap AF, Homering M, Tamm M, Weitz JI.

Blood Adv. 2018 Apr 10;2(7):788-796. doi: 10.1182/bloodadvances.2018017160.

41.

Impact of BMI on clinical outcomes of NOAC therapy in daily care - Results of the prospective Dresden NOAC Registry (NCT01588119).

Tittl L, Endig S, Marten S, Reitter A, Beyer-Westendorf I, Beyer-Westendorf J.

Int J Cardiol. 2018 Jul 1;262:85-91. doi: 10.1016/j.ijcard.2018.03.060. Epub 2018 Mar 14.

PMID:
29622509
42.

Effectiveness and Safety of Rivaroxaban Versus Warfarin in Frail Patients with Venous Thromboembolism.

Coleman CI, Turpie AGG, Bunz TJ, Beyer-Westendorf J.

Am J Med. 2018 Aug;131(8):933-938.e1. doi: 10.1016/j.amjmed.2018.02.015. Epub 2018 Mar 8.

PMID:
29526541
43.

Postthrombotic Syndrome in Patients Treated With Rivaroxaban or Warfarin for Venous Thromboembolism.

Coleman CI, Beyer-Westendorf J, Bunz TJ, Mahan CE, Spyropoulos AC.

Clin Appl Thromb Hemost. 2018 May;24(4):575-582. doi: 10.1177/1076029618758955. Epub 2018 Mar 8.

44.

Venous thromboembolism therapy with rivaroxaban in daily-care patients: Results from the Dresden NOAC registry.

Keller L, Marten S, Hecker J, Sahin K, Tittl L, Beyer-Westendorf J.

Int J Cardiol. 2018 Apr 15;257:276-282. doi: 10.1016/j.ijcard.2017.10.097.

PMID:
29506708
45.

What have we learned from real-world NOAC studies in venous thromboembolism treatment?

Beyer-Westendorf J.

Thromb Res. 2018 Mar;163:83-91. doi: 10.1016/j.thromres.2018.01.034. Epub 2018 Feb 6. Review.

PMID:
29407632
46.

Effectiveness and safety of outpatient rivaroxaban versus warfarin for treatment of venous thromboembolism in patients with a known primary hypercoagulable state.

Coleman CI, Turpie AGG, Bunz TJ, Baker WL, Beyer-Westendorf J.

Thromb Res. 2018 Mar;163:132-137. doi: 10.1016/j.thromres.2018.01.046. Epub 2018 Jan 31.

PMID:
29407625
47.
48.

Controversies in venous thromboembolism: to treat or not to treat superficial vein thrombosis.

Beyer-Westendorf J.

Hematology Am Soc Hematol Educ Program. 2017 Dec 8;2017(1):223-230. doi: 10.1182/asheducation-2017.1.223. Review.

49.

Use of Fondaparinux Off-Label or Approved Anticoagulants for Management of Heparin-Induced Thrombocytopenia.

Schindewolf M, Steindl J, Beyer-Westendorf J, Schellong S, Dohmen PM, Brachmann J, Madlener K, Pötzsch B, Klamroth R, Hankowitz J, Banik N, Eberle S, Müller MM, Kropff S, Lindhoff-Last E.

J Am Coll Cardiol. 2017 Nov 28;70(21):2636-2648. doi: 10.1016/j.jacc.2017.09.1099.

50.

Once- versus twice-daily direct oral anticoagulants in non-valvular atrial fibrillation.

Ageno W, Beyer-Westendorf J, Rubboli A.

Expert Opin Pharmacother. 2017 Sep;18(13):1325-1332. doi: 10.1080/14656566.2017.1361405. Epub 2017 Aug 11. Review.

PMID:
28786696

Supplemental Content

Loading ...
Support Center